Morgan Stanley
AVNR

Morgan Stanley’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Morgan Stanley’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,392,136
Closed -$23.6M – 6920
2014
Q4 		$23.6M Buy
1,392,136
+1,068,058
+330% +$15M 0.01% 1344
2014
Q3 		$3.86M Buy
324,078
+240,150
+286% +$1.64M ﹤0.01% 2856
2014
Q2 		$473K Buy
83,928
+16,748
+25% +$77.2K ﹤0.01% 4616
2014
Q1 		$246K Sell
67,180
-704,285
-91% -$2.68M ﹤0.01% 5012
2013
Q4 		$2.59M Buy
771,465
+1,737
+0.2% +$7.17K ﹤0.01% 3184
2013
Q3 		$3.25M Buy
769,728
+692,612
+898% +$3.28M ﹤0.01% 2832
2013
Q2 		$354K Buy
+77,116
New +$265K ﹤0.01% 4500

Morgan Stanley's AVNR Position: Q1 2015 in Review

Morgan Stanley sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2015, closing a stake of 1,392,136 shares — an estimated $23.6M sold.

Morgan Stanley first reported a position in AVNR in Q2 2013 and held it in 7 quarters. The position peaked at $23.6M in Q4 2014. 0 funds tracked by Wall St. Rank hold AVNR as of Q1 2015.

  • Morgan Stanley reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2015 after selling out during the quarter.
  • Morgan Stanley sold 1,392,136 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2015, an estimated $23.6M.
  • Morgan Stanley first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 7 quarters.
  • Morgan Stanley's AVANIR PHARMACEUTICALS, INC CL A position peaked at $23.6M in Q4 2014.
  • 0 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2015.

Based on Morgan Stanley's 13F filing for Q1 2015, filed 14 May 2015.